Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.47
ALXN's Cash-to-Debt is ranked lower than
89% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ALXN: 0.47 )
Ranked among companies with meaningful Cash-to-Debt only.
ALXN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3  Med: 2.79 Max: No Debt
Current: 0.47
Equity-to-Asset 0.66
ALXN's Equity-to-Asset is ranked lower than
51% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALXN: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
ALXN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.66 Max: 0.95
Current: 0.66
0.04
0.95
Debt-to-Equity 0.37
ALXN's Debt-to-Equity is ranked lower than
57% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. ALXN: 0.37 )
Ranked among companies with meaningful Debt-to-Equity only.
ALXN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.37 Max: 17.46
Current: 0.37
0
17.46
Debt-to-EBITDA 3.04
ALXN's Debt-to-EBITDA is ranked lower than
62% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ALXN: 3.04 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALXN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.28  Med: 0.26 Max: 5.01
Current: 3.04
-2.28
5.01
Interest Coverage 6.58
ALXN's Interest Coverage is ranked lower than
87% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 6.58 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 6.88  Med: 128.41 Max: 292.93
Current: 6.58
6.88
292.93
Piotroski F-Score: 8
Altman Z-Score: 4.05
Beneish M-Score: -2.64
WACC vs ROIC
8.30%
5.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 18.58
ALXN's Operating Margin % is ranked higher than
88% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ALXN: 18.58 )
Ranked among companies with meaningful Operating Margin % only.
ALXN' s Operating Margin % Range Over the Past 10 Years
Min: -138.47  Med: 25.18 Max: 38.9
Current: 18.58
-138.47
38.9
Net Margin % 14.57
ALXN's Net Margin % is ranked higher than
87% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ALXN: 14.57 )
Ranked among companies with meaningful Net Margin % only.
ALXN' s Net Margin % Range Over the Past 10 Years
Min: -128.11  Med: 17.12 Max: 76.31
Current: 14.57
-128.11
76.31
ROE % 5.77
ALXN's ROE % is ranked higher than
83% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ALXN: 5.77 )
Ranked among companies with meaningful ROE % only.
ALXN' s ROE % Range Over the Past 10 Years
Min: -81.59  Med: 14.48 Max: 63.11
Current: 5.77
-81.59
63.11
ROA % 3.77
ALXN's ROA % is ranked higher than
84% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ALXN: 3.77 )
Ranked among companies with meaningful ROA % only.
ALXN' s ROA % Range Over the Past 10 Years
Min: -27.64  Med: 9.66 Max: 46.71
Current: 3.77
-27.64
46.71
ROC (Joel Greenblatt) % 37.95
ALXN's ROC (Joel Greenblatt) % is ranked higher than
91% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ALXN: 37.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALXN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -88.09  Med: 55 Max: 173.84
Current: 37.95
-88.09
173.84
3-Year Revenue Growth Rate 20.50
ALXN's 3-Year Revenue Growth Rate is ranked higher than
74% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALXN: 20.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALXN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 33.55 Max: 462.4
Current: 20.5
0
462.4
3-Year EBITDA Growth Rate 18.90
ALXN's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ALXN: 18.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALXN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.9 Max: 73.2
Current: 18.9
0
73.2
3-Year EPS without NRI Growth Rate 11.50
ALXN's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. ALXN: 11.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALXN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.4  Med: 11.5 Max: 76
Current: 11.5
-19.4
76
GuruFocus has detected 2 Warning Signs with Alexion Pharmaceuticals Inc ALXN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALXN's 30-Y Financials

Financials (Next Earnings Date: 2018-02-16)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ALXN Guru Trades in Q4 2016

Eric Mindich 202,000 sh (New)
Manning & Napier Advisors, Inc 1,324,444 sh (+1142.33%)
Pioneer Investments 52,228 sh (+27.58%)
David Carlson 220,000 sh (+15.79%)
Frank Sands 5,585,268 sh (+6.47%)
Eaton Vance Worldwide Health Sciences Fund 207,828 sh (+13.14%)
John Paulson 200,000 sh (unchged)
John Paulson 153,000 sh (unchged)
Eric Mindich 200,000 sh (unchged)
John Paulson 153,341 sh (-32.66%)
Steven Cohen 398,200 sh (-34.88%)
Ron Baron 20,470 sh (-53.75%)
Joel Greenblatt 13,966 sh (-70.16%)
Paul Tudor Jones 1,700 sh (-98.89%)
» More
Q1 2017

ALXN Guru Trades in Q1 2017

Jim Simons 360,942 sh (New)
Ray Dalio 13,370 sh (New)
Paul Tudor Jones 7,037 sh (+313.94%)
John Paulson 334,200 sh (+117.95%)
Joel Greenblatt 21,450 sh (+53.59%)
David Carlson 320,000 sh (+45.45%)
Eaton Vance Worldwide Health Sciences Fund 234,509 sh (+12.84%)
John Paulson 200,000 sh (unchged)
Pioneer Investments 52,228 sh (unchged)
Ron Baron Sold Out
Eric Mindich Sold Out
Frank Sands 5,235,630 sh (-6.26%)
Manning & Napier Advisors, Inc 1,105,568 sh (-16.53%)
Steven Cohen 159,900 sh (-59.84%)
» More
Q2 2017

ALXN Guru Trades in Q2 2017

Mario Gabelli 4,000 sh (New)
Daniel Loeb 1,250,000 sh (New)
Steven Cohen 422,600 sh (+164.29%)
Joel Greenblatt 29,020 sh (+35.29%)
David Carlson 430,000 sh (+34.38%)
Frank Sands 6,346,074 sh (+21.21%)
Paul Tudor Jones 7,207 sh (+2.42%)
Pioneer Investments 52,228 sh (unchged)
Steven Cohen 200,000 sh (unchged)
John Paulson 200,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Jim Simons 212,300 sh (-41.18%)
Ray Dalio 6,398 sh (-52.15%)
John Paulson 103,200 sh (-69.12%)
Eaton Vance Worldwide Health Sciences Fund 143,788 sh (-38.69%)
» More
Q3 2017

ALXN Guru Trades in Q3 2017

George Soros 4,800 sh (New)
Ray Dalio 117,418 sh (+1735.23%)
Jim Simons 442,200 sh (+108.29%)
Paul Tudor Jones 13,425 sh (+86.28%)
Pioneer Investments 77,110 sh (+47.64%)
Joel Greenblatt 32,126 sh (+10.70%)
David Carlson 430,000 sh (unchged)
Mario Gabelli 4,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 143,788 sh (unchged)
John Paulson Sold Out
Daniel Loeb 1,000,000 sh (-20.00%)
Frank Sands 4,775,947 sh (-24.74%)
Steven Cohen 59,900 sh (-85.83%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Add 10.70%0.01%$121.08 - $146.69 $ 113.54-16%32,126
George Soros 2017-09-30 New Buy0.02%$121.08 - $146.69 $ 113.54-16%4,800
John Paulson 2017-09-30 Sold Out 0.17%$121.08 - $146.69 $ 113.54-16%0
John Paulson 2017-06-30 Reduce -69.12%0.37%$97.7 - $133.41 $ 113.54-2%103,200
Joel Greenblatt 2017-06-30 Add 35.29%0.01%$97.7 - $133.41 $ 113.54-2%29,020
Mario Gabelli 2017-06-30 New Buy$97.7 - $133.41 $ 113.54-2%4,000
John Paulson 2017-03-31 Add 117.95%0.29%$118.53 - $144.77 $ 113.54-12%334,200
Joel Greenblatt 2017-03-31 Add 53.59%0.01%$118.53 - $144.77 $ 113.54-12%21,450
Ron Baron 2017-03-31 Sold Out 0.01%$118.53 - $144.77 $ 113.54-12%0
John Paulson 2016-12-31 Reduce -32.66%0.1%$110.01 - $135.59 $ 113.54-7%153,341
Ron Baron 2016-12-31 Reduce -53.75%0.02%$110.01 - $135.59 $ 113.54-7%20,470
Joel Greenblatt 2016-12-31 Reduce -70.16%0.05%$110.01 - $135.59 $ 113.54-7%13,966
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:XKRX:068270, XKRX:207940, NAS:INCY, XMCE:GRF.P, OCSE:NZYM B, SZSE:002252, NAS:BMRN, XBRU:UCB, NAS:ALNY, NAS:VRTX, OCSE:GEN, HKSE:01177, NAS:KITE, NAS:SGEN, NAS:JAZZ, NAS:NKTR, NAS:ALKS, NAS:BLUE, NAS:EXEL, NAS:REGN » details
Traded in other countries:ALXN.Austria, AXP.Germany, ALXN.Mexico, ALXN.Switzerland, 0QZM.UK,
Headquarter Location:USA
Alexion Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Alexion Pharmaceuticals specializes in developing and marketing drugs for life-threatening medical conditions. Its blockbuster product is Soliris, the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders. Strensiq and Kanuma also target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Guru Investment Theses on Alexion Pharmaceuticals Inc

Spiros Segalas Commentary on Alexion Pharmaceuticals - Jul 10, 2017

In Health Care, Alexion Pharmaceuticals’ (NASDAQ:ALXN) weakness reflected investor concern about a change in senior management and disappointment that the Food and Drug Administration did not grant priority review for the company’s drug Soliris as a treatment for an ultra-rare form of myasthenia gravis. Soliris is already approved to treat two rare, genetic, and potentially life-threatening blood disorders. Other approved drugs target a disease caused by genetic mutations and an ultra-rare metabolic disorder.

From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.

Check out Spiros Segalas latest stock trades

Spiros Segalas on Alexion Pharmaceuticals - Aug 18, 2016



Many Health Care stocks that have been strong positive contributors to return over past quarters continued to face concerns about drug pricing. Biotechnology companies that sell innovative, high priced drugs lost ground, including Alexion Pharmaceuticals (NASDAQ:ALXN). We believe that the long-term fundamentals of the Fund’s biotechnology holdings remain intact, and that current valuations underestimate the potential of pipeline drugs.





From Spiros Segamas' Armiel Appreciation second quarter 2016 commentary.



Check out Spiros Segalas latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 23, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s investment thesis (innovative, exceptionally well-managed company with unique assets and pricing power) and we retain conviction.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 23, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 06, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell sharply in the first quarter as a result of the massive correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s story and we retain conviction. (Josh Riegelhaupt)





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - Feb 08, 2016

We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide.



From the Baron Funds Opportunity Fund fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Alexion Pharmaceuticals Inc

Factors of Influence in 2018, Key Indicators and Opportunity within Intuit, Alexion Pharmaceuticals, Salesforce, Jack In The Box, MedEquities Realty Trust, and Fiesta Restaurant Group — New Research Emphasizes Economic Growth
Investor Expectations to Drive Momentum within Carrizo, Coeur, Alexion, Ultra Clean, Alaska Air, and CA – Discovering Underlying Factors of Influence
ALEXION INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. - (ALXN)
Why Markets Might Have Got It Wrong With Omeros My take on the shorting situation
Omeros Corp. (NASDAQ:OMER) has spent the majority of the last few months as the subject of intense debate in the biotechnology space. The company, which is working to develop a variety of drugs targeting rare diseases, fell foul of a report published in June by a research group that goes by the pseudonym Art Doyle. The report attacked Omeros' lead development program, which is investigating the safety and efficacy of a drug called OMS721 in a target indication of atypical hemolytic uremic syndrome (aHUS), highlighting several so-called deficiencies associated with the current publicly available information to the program. Read more...
Spiros Segalas Commentary on Alexion Pharmaceuticals Guru stock highlight
In Health Care, Alexion Pharmaceuticals’ (NASDAQ:ALXN) weakness reflected investor concern about a change in senior management and disappointment that the Food and Drug Administration did not grant priority review for the company’s drug Soliris as a treatment for an ultra-rare form of myasthenia gravis. Soliris is already approved to treat two rare, genetic, and potentially life-threatening blood disorders. Other approved drugs target a disease caused by genetic mutations and an ultra-rare metabolic disorder. Read more...
Weekly Top Insider Buys Highlight for the Week of June 16 The largest Insider Buys were for Alexion Pharmaceuticals, Coty, Macy's and Range Resources
The largest Insider Buys this week were for Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Coty Inc. (NYSE:COTY), Macy's Inc. (NYSE:M) and Range Resources Corp (NYSE:RRC). Read more...
Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc., Intra-Cellular Therapies, Inc. and Twilio Inc.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN
Stocks That Fell to 3-Year Lows in the Week of May 19 Alexion Pharmaceuticals, Nielsen Holdings, Macerich Co. and Tractor Supply Co. have declined to their respective three-year lows
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Nielsen Holdings PLC (NYSE:NLSN), Macerich Co. (NYSE:MAC), and Tractor Supply Co. (NASDAQ:TSCO) have declined to their three-year lows. Read more...

Ratios

vs
industry
vs
history
PE Ratio 50.69
ALXN's PE Ratio is ranked lower than
74% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. ALXN: 50.69 )
Ranked among companies with meaningful PE Ratio only.
ALXN' s PE Ratio Range Over the Past 10 Years
Min: 13.83  Med: 73.48 Max: 961.82
Current: 50.69
13.83
961.82
Forward PE Ratio 16.29
ALXN's Forward PE Ratio is ranked higher than
59% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. ALXN: 16.29 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 50.69
ALXN's PE Ratio without NRI is ranked lower than
74% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. ALXN: 50.69 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALXN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.71  Med: 73.48 Max: 705.33
Current: 50.69
13.71
705.33
Price-to-Owner-Earnings 41.18
ALXN's Price-to-Owner-Earnings is ranked lower than
56% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. ALXN: 41.18 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALXN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.92  Med: 64.34 Max: 1108.89
Current: 41.18
15.92
1108.89
PB Ratio 2.83
ALXN's PB Ratio is ranked higher than
55% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALXN: 2.83 )
Ranked among companies with meaningful PB Ratio only.
ALXN' s PB Ratio Range Over the Past 10 Years
Min: 2.47  Med: 9.91 Max: 32.39
Current: 2.83
2.47
32.39
PS Ratio 7.40
ALXN's PS Ratio is ranked higher than
55% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ALXN: 7.40 )
Ranked among companies with meaningful PS Ratio only.
ALXN' s PS Ratio Range Over the Past 10 Years
Min: 6.77  Med: 15.57 Max: 893.33
Current: 7.4
6.77
893.33
Price-to-Free-Cash-Flow 29.78
ALXN's Price-to-Free-Cash-Flow is ranked higher than
51% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. ALXN: 29.78 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALXN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 25.34  Med: 60.26 Max: 4990
Current: 29.78
25.34
4990
Price-to-Operating-Cash-Flow 20.75
ALXN's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. ALXN: 20.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALXN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 18.2  Med: 47.18 Max: 83.95
Current: 20.75
18.2
83.95
EV-to-EBIT 41.06
ALXN's EV-to-EBIT is ranked lower than
73% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ALXN: 41.06 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -115.8  Med: 47.35 Max: 499.4
Current: 41.06
-115.8
499.4
EV-to-EBITDA 25.28
ALXN's EV-to-EBITDA is ranked lower than
62% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ALXN: 25.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -145  Med: 42.05 Max: 258.3
Current: 25.28
-145
258.3
EV-to-Revenue 7.81
ALXN's EV-to-Revenue is ranked higher than
57% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ALXN: 7.81 )
Ranked among companies with meaningful EV-to-Revenue only.
ALXN' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.2  Med: 15.4 Max: 891.8
Current: 7.81
7.2
891.8
PEG Ratio 1.91
ALXN's PEG Ratio is ranked lower than
56% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. ALXN: 1.91 )
Ranked among companies with meaningful PEG Ratio only.
ALXN' s PEG Ratio Range Over the Past 10 Years
Min: 0.68  Med: 2.37 Max: 11.23
Current: 1.91
0.68
11.23
Shiller PE Ratio 80.08
ALXN's Shiller PE Ratio is ranked lower than
76% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. ALXN: 80.08 )
Ranked among companies with meaningful Shiller PE Ratio only.
ALXN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 75.43  Med: 227.65 Max: 1466
Current: 80.08
75.43
1466
Current Ratio 2.97
ALXN's Current Ratio is ranked lower than
58% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALXN: 2.97 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.64 Max: 52.92
Current: 2.97
1.38
52.92
Quick Ratio 2.51
ALXN's Quick Ratio is ranked lower than
60% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ALXN: 2.51 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.3 Max: 52.92
Current: 2.51
1.38
52.92
Days Inventory 383.36
ALXN's Days Inventory is ranked lower than
93% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. ALXN: 383.36 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 366.37 Max: 959.95
Current: 383.36
202.61
959.95
Days Sales Outstanding 74.11
ALXN's Days Sales Outstanding is ranked lower than
57% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ALXN: 74.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.73  Med: 102.08 Max: 234.47
Current: 74.11
70.73
234.47
Days Payable 33.80
ALXN's Days Payable is ranked higher than
55% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. ALXN: 33.80 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 33.8  Med: 91.56 Max: 494.52
Current: 33.8
33.8
494.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
ALXN's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ALXN: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALXN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.9  Med: -9.5 Max: -2.4
Current: -4.4
-24.9
-2.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.70
ALXN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
65% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. ALXN: 1.70 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALXN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.7  Med: 5.26 Max: 142.22
Current: 1.7
1.7
142.22
Price-to-Median-PS-Value 0.48
ALXN's Price-to-Median-PS-Value is ranked higher than
76% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ALXN: 0.48 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALXN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.27 Max: 53.16
Current: 0.48
0.4
53.16
Price-to-Peter-Lynch-Fair-Value 2.85
ALXN's Price-to-Peter-Lynch-Fair-Value is ranked lower than
74% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. ALXN: 2.85 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ALXN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.56  Med: 2.93 Max: 10.86
Current: 2.85
0.56
10.86
Earnings Yield (Greenblatt) % 2.44
ALXN's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ALXN: 2.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALXN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.7  Med: 1.9 Max: 3.1
Current: 2.44
-10.7
3.1
Forward Rate of Return (Yacktman) % 20.07
ALXN's Forward Rate of Return (Yacktman) % is ranked higher than
70% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. ALXN: 20.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALXN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -18.5  Med: 0.55 Max: 75.6
Current: 20.07
-18.5
75.6

More Statistics

Revenue (TTM) (Mil) $3,472.00
EPS (TTM) $ 2.24
Beta1.14
Short Percentage of Float2.66%
52-Week Range $96.18 - 149.34
Shares Outstanding (Mil)223.41

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 3,511 4,098 4,788 5,484
EPS ($) 5.07 7.08 8.57 10.20
EPS without NRI ($) 5.07 7.08 8.57 10.20
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.80%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}